Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Liabilities and Shareholders Equity (2022 - 2025)

Historic Liabilities and Shareholders Equity for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to $44.8 million.

  • BioXcel Therapeutics' Liabilities and Shareholders Equity fell 838.58% to $44.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $147.5 million, marking a year-over-year decrease of 4544.7%. This contributed to the annual value of $38.3 million for FY2024, which is 4798.24% down from last year.
  • Latest data reveals that BioXcel Therapeutics reported Liabilities and Shareholders Equity of $44.8 million as of Q3 2025, which was down 838.58% from $25.8 million recorded in Q2 2025.
  • BioXcel Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $248.2 million during Q2 2022, with a 5-year trough of $25.8 million in Q2 2025.
  • Over the past 4 years, BioXcel Therapeutics' median Liabilities and Shareholders Equity value was $82.3 million (recorded in 2024), while the average stood at $116.6 million.
  • In the last 5 years, BioXcel Therapeutics' Liabilities and Shareholders Equity plummeted by 6419.68% in 2023 and then tumbled by 838.58% in 2025.
  • BioXcel Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $205.9 million in 2022, then plummeted by 64.2% to $73.7 million in 2023, then tumbled by 47.98% to $38.3 million in 2024, then increased by 16.83% to $44.8 million in 2025.
  • Its last three reported values are $44.8 million in Q3 2025, $25.8 million for Q2 2025, and $38.6 million during Q1 2025.